Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The role of radiotherapy in localised and locally advanced prostate cancer.

Bolla M, Henry A, Mason M, Wiegel T.

Asian J Urol. 2019 Apr;6(2):153-161. doi: 10.1016/j.ajur.2019.02.001. Epub 2019 Feb 8. Review.

2.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
3.

High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy.

Bolla M, Verry C, Long JA.

Curr Opin Urol. 2013 Jul;23(4):349-54. doi: 10.1097/MOU.0b013e328361ebfd. Review.

PMID:
23673512
4.

Management strategies for locally advanced prostate cancer.

Jani AB.

Drugs Aging. 2006;23(2):119-29. Review.

PMID:
16536635
5.

Technological advances in radiotherapy for the treatment of localised prostate cancer.

Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A.

Eur J Cancer. 2005 Apr;41(6):908-21. Review.

PMID:
15808957
6.

[Radiation therapy of locally advanced prostate cancer].

Schmidt-Hegemann NS, Li M, Eze C, Belka C, Ganswindt U.

Urologe A. 2017 Nov;56(11):1402-1409. doi: 10.1007/s00120-017-0511-4. Review. German.

PMID:
28983664
7.

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodríguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villà S, Perez de la Haza A, Calvo FA.

Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 19. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25702876
8.

The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.

Gunner C, Gulamhusein A, Rosario DJ.

J Clin Urol. 2016 Dec;9(2 Suppl):24-29. doi: 10.1177/2051415816654048. Epub 2016 Dec 1.

10.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
11.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

PMID:
25130995
12.

Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.

Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK.

J Urol. 2013 Aug;190(2):521-6. doi: 10.1016/j.juro.2013.02.012. Epub 2013 Feb 13.

PMID:
23415964
14.

Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.

Wilcox SW, Aherne NJ, McLachlan CS, McKay MJ, Last AJ, Shakespeare TP.

J Med Imaging Radiat Oncol. 2015 Feb;59(1):125-33. doi: 10.1111/1754-9485.12275. Epub 2015 Jan 15.

PMID:
25588566
15.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

16.

Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.

Luo HC, Cheng LP, Cheng HH, Fu ZC, Liao SG, Li DS, Zheng WF, Lin GS, Zhu JF, Xu JF, Yin Q, Yu QY.

Med Oncol. 2014 Jun;31(6):991. doi: 10.1007/s12032-014-0991-7. Epub 2014 May 22.

PMID:
24848281
17.

Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer.

Jereczek-Fossa BA, Orecchia R.

Radiother Oncol. 2007 Aug;84(2):197-215. Epub 2007 May 29. Review.

PMID:
17532494
18.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.

Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.

PMID:
27568654
19.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.

PMID:
30579763
20.

[Prostate cancer treatments in Belgium].

Kaitouni MI, Roumeguère T.

Rev Med Brux. 2009 Sep;30(4):270-8. French.

PMID:
19899373

Supplemental Content

Support Center